Compare Recursion Pharmaceuticals Inc (RXRX) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Vipshop Holdings Ltd - ADR trades at $12.8 (market cap $5.95B). The key difference: Vipshop Holdings Ltd - ADR is far larger — about 3.4× Recursion Pharmaceuticals Inc's market cap, and Vipshop Holdings Ltd - ADR pays a 4.96% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VIPS | |
|---|---|---|
Market Cap | $1.74B | $5.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $20.68 |
52-Week Low | $2.84 | $12.51 |
Enterprise Value | $1.26B | $2.78B |
Dividend Yield | — | 4.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Vipshop Holdings trades at $13.03, down 1.29% on the day, with bearish technical signals dominating despite attractive valuation metrics. The company reported mixed Q2 2026 results with significant earnings misses, though maintains strong profitability with 9.82% net margin and 24.44% ROE. Recent institutional activity includes Nykredit A/S establishing a $2.35 million position in Q2 2026.
The stock presents a value opportunity with P/E of 4.21 and P/S of 0.41, but faces headwinds from declining revenue and challenging consumer sentiment. Analyst consensus leans bullish with 53.57% buy ratings, though technical indicators suggest near-term pressure. Key risks include Chinese consumer spending weakness and competitive pressures in e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
